NOVARTIS

Beovu®
brolucizumab

Beovu® is indicated in adults for the treatment of neovascular (wet) age-related macular degeneration (AMD).

Beovu PI\PL

AZARGA®
brinzolamide 10mg/ml+timolol (as maleate) 5mg/ml, ophthalmic suspension

Decrease of intraocular pressure (IOP) in adult patients with open-angle glaucoma or ocular hypertension for whom monotherapy provides insufficient IOP reduction.

Azarga PI\PL

SIMBRINZA®
10 mg/ml +2 mg/ml eye drops suspension (brinzolamide/ brimonidine tartrate)

Decrease of elevated intraocular pressure (IOP) in adult patients with open-angle glaucoma or ocular hypertension for whom monotherapy provides insufficient IOP reduction

Simbrinza PI\PL

LUCENTIS®
RANIBIZUMAB

Treatment of patients with neovascular (wet) age-related macular degeneration (AMD)
- Treatment of adult patients with visual impairment due to diabetic macular oedema (DME)
- The treatment of proliferative diabetic retinopathy (PDR)
- The treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (RVO)
- The treatment of visual impairment due to choroidal neovascularisation (CNV)

Lucentis is indicated in preterm infants for:
- The treatment of retinopathy of prematurity (ROP) with zone I (stage 1+, 2+, 3 or 3+), zone II (stage 3+) or AP-ROP (aggressive posterior ROP) disease.

Lucentis PI\PL

Nevanac®
nepafenac 0.1% ophthalmic suspension

NEVANAC is indicated in adults for:
- Prevention and treatment of postoperative pain and inflammation associated with cataract surgery
- Reduction in the risk of postoperative macular oedema associated with cataract surgery in diabetic patients.

Nevanac PI\PL

LUXTURNA®
voretigene neparvovec
for subretinal injection

Luxturna is indicated for the treatment of adult and paediatric patients with vision loss due to inherited retinal dystrophy caused by confirmed biallelic RPE65 mutations and who have sufficient viable retinal cells.

Luxturna PI\PL

OPH-LAN-02.22 May-2022

NOVARTIS Novartis Israel Ltd. 6 Totzeret Haaretz St. Tel Aviv 6744129 Israel , TEL: 03-9201111, FAX: 03-9229331